Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ozenoxacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A | P11388 | 8/20 | 0.45 |
| ▸ | TOP2B | Q02880 | 8/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.40 |
| ▸ | GSK3B | P49841 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ozenoxacin SCHEMBL29379004 | 1.00 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2551660 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2551666 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2553345 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2550848 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2553340 | 0.99 | TOP2A (0.45) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2548603 | 0.98 | TOP2A (0.44) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2553347 | 0.96 | TOP2A (0.43) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2550845 | 0.96 | TOP2A (0.42) | TOP2ATOP2BKCNH2GSK3BKDM4E | |
| Ozenoxacin SCHEMBL2550846 | 0.96 | TOP2A (0.42) | TOP2ATOP2BKCNH2GSK3BKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 114 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11439634-B2 | Medical skin external preparation | MARUHO CO., LTD. (JP) | 2022-09-13 | — | — | US | claimed |
| US-20210128548-A1 | EXTERNAL PREPARATION COMPRISING PYRIDONECARBOXYLIC ACID DERIVATIVE | MARUHO CO., LTD. (JP) | 2021-05-06 | — | — | US | claimed |
| WO-2020065668-A1 | CRYSTALLINE FORM OF OZENOXACIN AND PROCESSES FOR PREPARATION THEREOF | MAITHRI DRUGS PVT LTD (IN) | 2020-04-02 | — | — | WO | claimed |
| EP-3549586-A1 | MEDICAL SKIN EXTERNAL PREPARATION | Maruho Co., Ltd. (JP) | 2019-10-09 | — | — | EP | claimed |
| US-20190282562-A1 | MEDICAL SKIN EXTERNAL PREPARATION | MARUHO CO., LTD. (JP) | 2019-09-19 | — | — | US | claimed |
| US-20180021329-A1 | EXTERNAL PREPARATION COMPRISING PYRIDONECARBOXYLIC ACID DERIVATIVE | MARUHO CO., LTD. (JP) | 2018-01-25 | — | — | US | claimed |
| EP-3257512-A1 | EXTERNAL PREPARATION COMPRISING PYRIDONECARBOXYLIC ACID DERIVATIVE | Maruho Co., Ltd. (JP) | 2017-12-20 | — | — | EP | claimed |
| EP-1731138-B1 | FINE DISPERSION OF SPARINGLY SOLUBLE DRUG AND PROCESS FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO LTD (JP) | 2016-03-23 | — | — | EP | claimed |
| EP-1941880-B1 | LOTION PREPARATION CONTAINING PYRIDONECARBOXYLIC ACID DERIVATIVE | MARUHO KK (JP) | 2015-10-28 | — | — | EP | claimed |
| EP-2556063-B1 | 1-CYCLOPROPYL-8-METHYL-7-[5-METHYL-6-(METHYLAMINO)-3-PYRIDINYL]-4-OXO-1,4-DIHYDRO-3-QUINOLINECARBOXYLIC ACID SALTS | FERRER INT (ES) | 2015-07-01 | — | — | EP | claimed |
| US-20080166398-A1 | Sertaconazole and hydrocortisone; for dermal diseases; inflammation | FERRER INTERNACIONAL, S.A. (ES) | 2008-07-10 | — | — | US | claimed |
| EP-1941880-A1 | LOTION PREPARATION CONTAINING PYRIDONECARBOXYLIC ACID DERIVATIVE | MARUHO Co., Ltd. (JP) | 2008-07-09 | — | — | EP | claimed |
| EP-1858510-A1 | ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND | FERRER INTERNACIONAL, S.A. (ES) | 2007-11-28 | — | — | EP | claimed |
| US-20070224282-A1 | Fine Dispersion of Sparingly Soluble Drug and Process for Producing the Same | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-09-27 | — | — | US | claimed |
| EP-1731138-A1 | FINE DISPERSION OF SPARINGLY SOLUBLE DRUG AND PROCESS FOR PRODUCING THE SAME | TOYAMA CHEMICAL CO., LTD. (JP) | 2006-12-13 | — | — | EP | claimed |
| EP-1070713-B1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO LTD (JP) | 2006-10-18 | — | — | EP | claimed |
| WO-2006092374-A1 | ANTIFUNGAL COMPOSITIONS COMPRISING SERTACONAZOL AND HYDROCORTISONE AND/OR AN ANTIBACTERIAL QUINOLONE COMPOUND | FERRER INTERNACIONAL, S. A. (ES) | 2006-09-08 | — | — | WO | claimed |
| EP-1698336-A1 | Antifungal compositions comprising Sertaconazole and either Hydrocortisone or an antibacterial agent | FERRER INTERNACIONAL, S.A. (ES) | 2006-09-06 | — | — | EP | claimed |
| US-6335447-B1 | BACTERICIDES | TOYAMA CHEMICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | claimed |
| EP-1070713-A1 | QUINOLONECARBOXYLIC ACID DERIVATIVES OR SALTS THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2001-01-24 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282562-A1 | MEDICAL SKIN EXTERNAL PREPARATION | CUTA, TLR8, TLR7 | TOP2A 980/4885TOP2B 1717/4885KCNH2 591/4885 |
| US-11439634-B2 | Medical skin external preparation | CUTA, TLR8, TLR7 | TOP2A 980/4885TOP2B 1717/4885KCNH2 591/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.